课题基金 / 基金详情

CNTF Receptors: Neuromuscular Protection/Repair In Vivo

CNTF Receptors: Neuromuscular Protection/Repair In Vivo
CNTF 受体:体内神经肌肉保护/修复
批准号:
7100043
负责人:
Alexander John MacLennan
金额:
$34.54万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-10 至 2010-04-30

项目摘要

项目成果

Alexander John MacLennan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Several lines of evidence suggest that endogenous ciliary neurotrophic factor (CNTF) receptor signaling may promote neuromuscular protection and repair. Thus, proper targeting of CNTF receptor signaling may selectively counteract the devastating effects of neuromuscular disorders by appropriately enhancing these naturally evolved mechanisms. Unfortunately, current understanding of endogenous CNTF receptor function in the adult is extremely limited because blockage of the receptor in vivo (through disruption of the critical CNTF receptor a [CNTFRa] gene) leads to perinatal death. To overcome this problem, we will use Cre/lox techniques to selectively disrupt the CNTFRa gene. Specific Aim 1 will examine the contribution of CNTF receptor signaling to the survival, protection and phenotype maintenance of adult motor neurons. The CNTFRa gene will be disrupted in facial motor neurons of "floxed" CNTFRa mice with: 1) stereotaxic injection of the facial nucleus with an adeno-associated virus that directs Cre recombinase (Cre) expression and 2) a gene construct enabling temporally controlled induction of Cre activity. Preliminary data indicate an essential in vivo role for CNTFRa in adult motor neuron survival. We will quantitatively characterize this function with reporter genes, immunohistochemistry and stereological cell counting and also determine whether insult is required to activate this neuroprotective system (as preliminary data suggest), and if so, what forms of insult. In addition, a reporter gene and immunohistochemistry will be used to determine whether CNTF receptor signaling maintains motor neuron cholinergic phenotype in vivo. Finally, signaling proteins potentially involved in the neuroprotection will be identified through in situ hybridization and immunohistochemistry. Specific Aim 2 will define the role of skeletal muscle CNTFRa in neuromuscular protection and repair. Preliminary data from floxed CNTFRa mice with skeletal muscle specific Cre expression reveal that muscle CNTFRa is required for normal motor recovery following peripheral nerve lesion. We will characterize this functional deficit with "footprint" analysis and identify the underlying cellular mechanisms by quantifying: 1) neuromuscular junction formation, 2) motor neuron survival and cholinergic phenotype, and 3) muscle contractility. In addition, STAT3-based immunohistochemistry will be used to localize cellular sites of muscle-CNTFRa-dependent signaling after nerve lesion. Moreover, microarray analysis of muscle and spinal cord ventral grey matter following nerve lesion will be used to identify novel candidate genes potentially involved in the critical CNTF receptor signaling. Relevance in lay language: We will determine how natural CNTF receptor signaling in mice protects and repairs the adult neuromuscular system. The resulting knowledge should facilitate the design of therapeutics which selectively enhance the appropriate CNTF receptor signaling and thereby effectively treat neuromuscular disease while avoiding side effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Gene Therapy Targeting of CNTFRalpha and CLC in Muscle to Treat ALS
  • 批准号:
    10427242
  • 项目类别:
  • 资助金额:
    $40.59万
  • 财政年份:
    2019
  • 负责人:
    Alexander John MacLennan
  • 依托单位:
Gene Therapy Targeting of CNTFRalpha and CLC in Muscle to Treat ALS
  • 批准号:
    10017338
  • 项目类别:
  • 资助金额:
    $41.79万
  • 财政年份:
    2019
  • 负责人:
    Alexander John MacLennan
  • 依托单位:
Gene Therapy Targeting of CNTFRalpha and CLC in Muscle to Treat ALS
  • 批准号:
    10171631
  • 项目类别:
  • 资助金额:
    $40.59万
  • 财政年份:
    2019
  • 负责人:
    Alexander John MacLennan
  • 依托单位:
Gene Therapy Targeting of CNTFRalpha and CLC in Muscle to Treat ALS
  • 批准号:
    10634588
  • 项目类别:
  • 资助金额:
    $40.59万
  • 财政年份:
    2019
  • 负责人:
    Alexander John MacLennan
  • 依托单位:
国内基金
海外基金
多孔Ti-MSNs@MGF+DX抗炎—成肌体系应用于颞下颌关节假体的作用和机制研究
  • 批准号:
    82370984
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    郑吉驷
  • 依托单位:
GASP-1通过Myostatin信号通路调控颏舌肌功能的作用及机制研究
  • 批准号:
    82371131
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    易红良
  • 依托单位:
骨骼肌中胰高血糖素受体的表达及其调控血糖稳态的作用与机制研究
  • 批准号:
    82370820
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    王天歌
  • 依托单位:
LIPUS促进微环境巨噬细胞释放CCL2诱导尿道周围平滑肌祖细胞定植与分化的机制研究
  • 批准号:
    82370780
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    夏术阶
  • 依托单位: